

Therapeutic Advancements in Myelodysplastic Syndromes

Bridging the Gap Between Patient Safety and Quality Care Through the Latest Science and Evidence-Based Learning in Nursing Practice

CME/MOC/NCPD/ILNA Post-Test, Answer Key, and Evaluation Form

PeerView
Live



Mail to:
**PVI, PeerView Institute
for Medical Education**
174 W. 4th Street, Suite 181
New York, NY 10014

Fax to:
877-572-0781

Email to:
info@PeerView.com

Online:
PeerView.com/MDS-Survey-EQN

To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete the post-test and evaluation form. The Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education, respect and appreciate your opinions. You may return this post-test and evaluation form on-site to a PeerView staff member or via mail, fax, or email. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/NCPD/ILNA credit.

CME: In order to receive a Statement of Credit, you must complete and submit the request for credit.

MOC/CC: If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

NCPD: In order to receive a Statement of Credit, all post-test questions below are required. A score of 70% or higher is needed to obtain NCPD credit.

This CME/MOC/NCPD activity is provided by Medical Learning Institute, Inc.

This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education.



Request for Credit

Physician Continuing Medical Education: Please complete the following:

This live activity has been certified for a maximum of 1.0 *AMA PRA Category 1 Credit*™. Physicians should only claim credit commensurate with the extent of their participation in the activity (15 minutes = 0.25 credit).

I certify my actual time spent to complete this live activity to be (you may select up to two answers)

- ☐ I participated in the entire activity and claim 1.0 *AMA PRA Category 1 Credit*™
- ☐ I participated in part of the activity and claim ____ *AMA PRA Category 1 Credit*™

- ☐ I participated in the entire activity and request 1.0 ABIM MOC points.
- ☐ I participated in part of the activity and request ____ ABIM MOC points.

By checking the box I permit MLI to report my completion information through the ACCME's Program and Activity Reporting System (PARS).

Nursing Continuing Professional Development: Please complete the following:

- ☐ I participated in the entire activity and claim 1.0 contact hour(s).

Therapeutic Advancements in Myelodysplastic Syndromes

Bridging the Gap Between Patient Safety and Quality Care Through the Latest Science and Evidence-Based Learning in Nursing Practice

CME/MOC/NCPD/ILNA Post-Test, Answer Key, and Evaluation Form



Contact Information (*required)

*First Name:	*Last Name:
*Degree:	Specialty:
*Address:	
*City:	*State/Province:
*ZIP/Postal Code:	*Country:
Phone Number:	Fax Number:
*Email (required for electronic copy of Statement of Credit):	
*MOC/CC Board Unique ID Number (required for all except ABA, ABP, ABS):	License Number:
*Date of Birth - MM/DD (required for all except ABA, ABP, ABS):	

☐ I would like to receive email alerts about upcoming PeerView educational activities.

Therapeutic Advancements in Myelodysplastic Syndromes

Bridging the Gap Between Patient Safety and Quality Care Through the Latest Science and Evidence-Based Learning in Nursing Practice

CME/MOC/NCPD/ILNA Post-Test, Answer Key, and Evaluation Form



CME/MOC/NCPD/ILNA Post-Test (Please write the letter of your answer in the assigned circle.)

1. Which of the following factors would you consider sufficient to diagnose myelodysplastic syndromes (MDS) according to the 2016 WHO classification?

- a. Excess marrow blasts $\geq 20\%$
- b. MDS-type mutation
- c. Dysplastic morphology $> 10\%$
- d. Flow cytometry abnormality
- e. I'm not sure

Your Answer

☐

2. A 65-year-old woman presents at your clinic for management of RBC transfusion-dependent, erythropoietin-stimulating agent (ESA)-resistant MDS. Her laboratory values show Hb 7.4 g/dL, no other cytopenia, 2% blasts, 10% ring sideroblasts, normal cytogenetics, and SF3B1 mutation. Which of the following treatment options would you discuss with this patient and recommend as the most appropriate next step? Assume a donor is available for stem cell transplant.

- a. Venetoclax
- b. Luspatercept
- c. Immunosuppressive therapy
- d. Allogeneic bone marrow transplant
- e. I'm not sure

Your Answer

☐

3. Which of the following statements best summarizes the mechanisms of action for magrolimab?

- a. It stimulates T cells via PD-1/PD-L1 blockade and leads to cancer cell death
- b. It's an anti-CD47 antibody that promotes phagocytosis of cancerous cells leading to their therapeutic elimination
- c. It's a cytidine deaminase inhibitor that improves oral availability of DNA methyltransferase inhibitors (DNMTi)
- d. It can then trigger cell cycle arrest leading to apoptosis of cancer cells
- e. I'm not sure

Your Answer

☐

4. Which of the following statements best summarizes data on treatment-emergent adverse events (TEAEs) based on the results of the phase 1b trial evaluating sabatolimab in combination with a DNMTi (decitabine or azacitidine)?

- a. The most common grade ≥ 3 TEAEs with sabatolimab + a DNMTi were cough, epistaxis, pneumonia, and dyspnea
- b. Higher incidence (30%) of grade ≥ 3 TEAEs was seen with sabatolimab + a DNMTi vs a DNMTi alone
- c. The most common grade ≥ 3 TEAEs with sabatolimab + a DNMTi were thrombocytopenia, neutropenia, febrile neutropenia, and anemia
- d. Discontinuation due to TEAEs was frequent (25%) with sabatolimab + a DNMTi in the very high-risk and high-risk MDS cohort
- e. I'm not sure

Your Answer

☐

5. A 62-year-old man is referred to you for management of HR-MDS with TP53 mutation. His bone marrow biopsy is suggestive of hypercellular marrow (62%) and dyserythropoiesis with 7% blasts, and his Hb is 8.1 gm/dL. He hasn't received previous treatment with a DNMTi agent. Which of the following clinical trials would you recommend to this patient?

- a. A trial testing the combination of CC-486 + lenalidomide
- b. A trial testing the combination of decitabine + cedazuridine
- c. A trial testing the combination of a DNMTi with pevonedistat, magrolimab, or sabatolimab
- d. A trial testing the combination of lenalidomide + cedazuridine
- e. I'm not sure

Your Answer

☐

6. Assume you are managing a 70-year-old patient with lower-risk MDS on therapy with the erythroid maturation agent luspatercept; how would you plan to anticipate/manage potential toxicities associated with this agent?

- a. Monitor for events such as fatigue, diarrhea, asthenia, nausea, and dizziness
- b. Monitor for events such as pneumonia, dyspnea, hypoglycemia, and thyroiditis
- c. Monitor for events such as infection, hyperglycemia, and rash/cutaneous reactions
- d. Monitor for events such as hypotonia, hypomagnesemia, and elevated ALT and AST

Your Answer

☐

Therapeutic Advancements in Myelodysplastic Syndromes

Bridging the Gap Between Patient Safety and Quality Care Through the Latest Science and Evidence-Based Learning in Nursing Practice

CME/MOC/NCPD/ILNA Post-Test, Answer Key, and Evaluation Form



CME/MOC/NCPD/ILNA Activity Evaluation Form (Please mark your answer with a circle.)

1. To what extent have the information and practice strategies discussed in this activity improved your ability to competently manage patients/support patient care?

Not at all			Very much		
1	2	3	4	5	N/A

2. After participating in this activity, how often do you plan to do the following?

	Never	Infrequently	Sometimes	Frequently	Always	
Consider IPSS-R scoring and prognostic impact of mutations in newly diagnosed patients with MDS	1	2	3	4	5	N/A
Inform patients about current and emerging therapeutic options for managing transfusion-dependent anemia in LR-MDS	1	2	3	4	5	N/A
Counsel and encourage patients for enrollment in clinical trials evaluating novel therapies or DNMTi-based combinations in HR-MDS	1	2	3	4	5	N/A
Develop educational strategies for patients with MDS related to therapeutic expectations, treatment adherence, and safety considerations	1	2	3	4	5	N/A
Educate patients about treatment-related adverse events and develop plans for managing toxicities to enhance QOL for patients with MDS	1	2	3	4	5	N/A

3. Please indicate your level of agreement with the following statements:

	Strongly disagree				Strongly agree
The content was presented in a fair and unbiased manner.	1	2	3	4	5
The content was evidence-based.	1	2	3	4	5
The content was relevant to my practice.	1	2	3	4	5
The format of this activity was useful and conducive to learning.	1	2	3	4	5
The faculty demonstrated expertise in subject matter.	1	2	3	4	5
The interactive questions positively impacted my learning.	1	2	3	4	5

4. As a result of your participation in this activity, please indicate your ability to meet each of the stated educational objectives.

	Not able				Very able
Review clinical presentation, diagnostic-prognostic workups, risk stratification, and identification of transfusion needs of patients with MDS	1	2	3	4	5
Interpret recent clinical evidence on currently approved and innovative emerging treatment strategies for managing low-risk as well as high-risk patients with MDS	1	2	3	4	5
Develop educational strategies for patients with MDS related to therapeutic expectations, adherence, safety considerations, and differences among novel agent classes	1	2	3	4	5
Employ strategies to manage treatment-related adverse events to enhance quality of life for patients with MDS	1	2	3	4	5

Therapeutic Advancements in Myelodysplastic Syndromes

Bridging the Gap Between Patient Safety and Quality Care Through the Latest Science and Evidence-Based Learning in Nursing Practice

CME/MOC/NCPD/ILNA Post-Test, Answer Key, and Evaluation Form

5. Please indicate the likelihood of the following statements:

	Not at all likely				Very likely
I will make changes to my practice after participating in this activity.	1	2	3	4	5
Practice changes I make based on this activity will improve my and the healthcare teams' ability to affect patients' outcomes.	1	2	3	4	5
I would participate in future activities on this topic presented in a similar format.	1	2	3	4	5
I would recommend this activity to my colleagues.	1	2	3	4	5

6. Which of the following barriers or challenges that you encounter in your care of patients or practice will this activity help you overcome? (Indicate all that apply.)

- ☐ Engaging patients and caregivers in shared decision making
 ☐ Coordinating care with interprofessional team
- ☐ Patient adherence
 ☐ Decision making in the presence of conflicting evidence
- ☐ Lack of training/experience with this specific topic
 ☐ Cost/Reimbursement/Therapy Approval Status
- ☐ Other (please specify): Detailed feedback is encouraged and appreciated _____

☐ None; I do not encounter barriers in the care of patients/my practice

7. As a result of participating in this activity and as part of the healthcare team, I will: (Indicate all that apply.)

- ☐ Recognize and gain a better understanding of the roles and responsibilities of the healthcare team in improving patient outcomes
- ☐ Apply tools and techniques for better communication with patients and caregivers
- ☐ Work as a collaborative team to improve patient care and safety
- ☐ Utilize appropriate use of specialists and clinical resources to improve health outcomes
- ☐ Other (please specify): Detailed feedback is encouraged and appreciated _____

8. Do you intend to change your practice as a result of participating in this activity? ☐ Yes ☐ No If so, how? If not, why not?

9. Please provide any other feedback or comments regarding this activity.